Nexiclon Xr is a drug owned by Athena Bioscience Llc. It is protected by 2 US drug patents filed in 2020 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 08, 2031. Details of Nexiclon Xr's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US8337890 | Modified release formulations containing drug-ion exchange resin complexes |
Apr, 2027
(2 years from now) | Active |
| US8623409 | Clonidine formulation |
Sep, 2031
(7 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Nexiclon Xr's patents.
Latest Legal Activities on Nexiclon Xr's Patents
Given below is the list of recent legal activities going on the following patents of Nexiclon Xr.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 May, 2024 | US8337890 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 Jun, 2021 | US8623409 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Jun, 2020 | US8337890 |
| Correspondence Address Change | 04 Apr, 2014 | US8337890 |
| Recordation of Patent Grant Mailed | 07 Jan, 2014 | US8623409 |
| Patent Issue Date Used in PTA Calculation | 07 Jan, 2014 | US8623409 |
| Email Notification | 19 Dec, 2013 | US8623409 |
| Issue Notification Mailed | 18 Dec, 2013 | US8623409 |
| Dispatch to FDC | 13 Dec, 2013 | US8623409 |
| Email Notification | 10 Dec, 2013 | US8623409 |
US patents provide insights into the exclusivity only within the United States, but Nexiclon Xr is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Nexiclon Xr's family patents as well as insights into ongoing legal events on those patents.
Nexiclon Xr's family patents
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Generic Launch
Generic Release Date:
Nexiclon Xr's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 08, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Nexiclon Xr Generics:
Clonidine is the generic name for the brand Nexiclon Xr. 4 different companies have already filed for the generic of Nexiclon Xr, with Actavis Labs Ut Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Nexiclon Xr's generic
About Nexiclon Xr
Nexiclon Xr is a drug owned by Athena Bioscience Llc. It is used for treating high blood pressure, chest pain, and heart failure. Nexiclon Xr uses Clonidine as an active ingredient. Nexiclon Xr was launched by Athena in 2009.
Market Authorisation Date:
Nexiclon Xr was approved by FDA for market use on 03 December, 2009.
Active Ingredient:
Nexiclon Xr uses Clonidine as the active ingredient. Check out other Drugs and Companies using Clonidine ingredient
Treatment:
Nexiclon Xr is used for treating high blood pressure, chest pain, and heart failure.
Dosage:
Nexiclon Xr is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.17MG BASE | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| EQ 0.26MG BASE | TABLET, EXTENDED RELEASE | Discontinued | ORAL |